Navigation Links
A hot road to new drugs
Date:2/24/2010

The search for new therapeutic agents is time-consuming and expensive. Pharmaceutical companies may have to screen thousands of compounds for the ability to bind a target molecule before they hit upon a promising drug candidate. A group of Biophysicists at LMU Munich led by Professor Dieter Braun, a member of the Cluster of Excellence "Nanosystems Initiative Munich" (NIM), and a partner in NanoTemper (an LMU spin-off), have now developed a unique technology called "microscale thermophoresis" that allows to measure intereactions under close-to-native conditions, thus improving the decision making process in drug development. The technique takes advantage of the Soret effect the tendency of molecules to drift along temperature gradients, usually from warm to cold. If a compound encounters and binds to another molecule, its thermophoretic parameters change, and its trajectory may even be reversed. This phenomenon can be exploited to determine whether a molecule that is known to play a causative role in a given disease binds to a test substance. In the test, which can be carried out directly on blood samples, the thermodiffusion of a labelled biomolecule of interest is measured in the presence and absence of a candidate binding agent. If the two bind together to form a complex, the resulting change in their thermophoretic behaviour can be detected. "Detection of binding activity is the first step on the road to a new drug", says Braun. "The new method also has potential applications in medical diagnostics, and in food and environmental monitoring."

The procedures conventionally used to identify candidate drugs are normally carried out in artificial buffer solutions, and the results often have little relationship to a compound's binding affinity for its target in the blood. The new thermophoretic technique, on the other hand, allows one to perform the binding test directly in a blood sample and therefore gives more reliable results. The substance to be tested is mixed with a blood sample containing a target that is known to be associated with a disease state and has been labelled with a fluorescent tag. A tiny drop of the mixture is taken up into a thin glass capillary tube, and a focused beam of IR-laser light is used to heat a small volume of the solution in the middle of the tube. This gives rise to a temperature gradient that falls off towards the outside. The response of the labelled molecule to the variation in temperature can then be followed using fluorescence methods.

Upon heating of the sample, it immediately becomes apparent whether or not the fluorescent target-molecules in the sample behave differently in the presence of the drug test compound than they do in its absence. Any difference in thermophoresis between the two samples indicates that the test substance binds to the labelled target, and provides the first hint that it may have therapeutic potential. "Our method will not only be a boon to drug discovery", says Braun. "It can also be used in medical diagnostics, food testing and environmental monitoring. One could, for instance, employ it to diagnose autoimmune diseases and infections, or as the basis for a rapid test for the presence of antibiotics in milk or toxic substances in water." (NIM/suwe)


'/>"/>

Contact: Prof. Dieter Braun
49-892-180-2317
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
4. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
5. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
6. So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market
7. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
8. Amazing Treatment Relieves Serious Back Pain Without Dangerous Drugs, Injections or Surgery!
9. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
10. Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs
11. Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 25, 2017 , ... Proscia Inc. , a software solutions provider ... panelist at 2017 MedCity CONVERGE. His talk, “The Davids vs. the Cancer Goliath,” will ... emerging technology (AI, VR, Big Data) sectors are taking aim at cancer diagnosis and ...
(Date:7/26/2017)... Yorba Linda, Ca (PRWEB) , ... July 25, ... ... will host August 22, attendees will garner a better understanding of the considerations ... for HDR-mediated CRISPR-Cas9 applications. , The use of CRISPR-Cas9 to create targeted double-strand ...
(Date:7/26/2017)... ... July 26, 2017 , ... Spectral imaging is a ... day. This unique capability combines high resolution imaging with spectral analysis. ... unprecedented datasets for chemical analysis, quality control, and decision-making. , Snapshot spectral imaging ...
(Date:7/26/2017)... ... July 26, 2017 , ... Joni Rutter, Director ... Institutes of Health (NIH), will be one of the esteemed presenters at the ... for a multi-stakeholder discussion on the latest advancements in the precision and personalized ...
Breaking Biology Technology:
(Date:6/14/2017)... 15, 2017  IBM (NYSE: IBM ) is introducing several ... dedicated to developing collaboration between startups and global businesses, taking ... During the event, nine startups will showcase the solutions they ... industries. France is ... with a 30 percent increase in the number of startups ...
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
(Date:4/17/2017)... MELBOURNE, Florida , April 17, 2017 ... security technology company, announces the filing of its 2016 Annual Report ... Securities and Exchange Commission. ... Report on Form 10-K is available in the Investor Relations section ... well as on the SEC,s website at http://www.sec.gov . ...
Breaking Biology News(10 mins):